RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Pharmaceuticals Stock

GlaxoSmithKline Pharmaceuticals P/S 2024

GlaxoSmithKline Pharmaceuticals P/S

12.24

Ticker

GLAXO.NS

ISIN

INE159A01016

As of Jul 11, 2024, GlaxoSmithKline Pharmaceuticals's P/S ratio stood at 12.24, a 76.62% change from the 6.93 P/S ratio recorded in the previous year.

The GlaxoSmithKline Pharmaceuticals P/S history

GlaxoSmithKline Pharmaceuticals Aktienanalyse

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding GlaxoSmithKline Pharmaceuticals's P/S Ratio

GlaxoSmithKline Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing GlaxoSmithKline Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating GlaxoSmithKline Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in GlaxoSmithKline Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals stock

What is the price-to-earnings ratio of GlaxoSmithKline Pharmaceuticals?

The price-earnings ratio of GlaxoSmithKline Pharmaceuticals is currently 12.24.

How has the price-earnings ratio of GlaxoSmithKline Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of GlaxoSmithKline Pharmaceuticals has increased by 76.62% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of GlaxoSmithKline Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of GlaxoSmithKline Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of GlaxoSmithKline Pharmaceuticals affect the company?

An increase in the price-earnings ratio of GlaxoSmithKline Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of GlaxoSmithKline Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of GlaxoSmithKline Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of GlaxoSmithKline Pharmaceuticals?

Some factors that influence the price-earnings ratio of GlaxoSmithKline Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 32 INR . This corresponds to a dividend yield of about 1.27 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 26.71 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 1.27 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, August, July, June.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 26.71 INR are expected. This corresponds to a dividend yield of 1.06 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 7/1/2024 amounting to 32 INR, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2023?

In the year 2023, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.